merck moderna - Search News

Moderna, Merck and melanoma vaccine

Merck and Moderna say cancer vaccine shows promise in preventing recurrence of melanoma

Pharmaceutical giants Moderna and Merck said Wednesday that an experimental vaccine treatment has shown signs of preventing cancer from returning or spreading in a study of high-risk melanoma patients...

· 8h

Moderna, Merck See Promise in Experimental Skin Cancer Vaccine

· 23h · on MSN

Cancer vaccine from Moderna, Merck shows promise in late-stage trial; both stocks soar

· 1d

Moderna Shares Surge After It Says Its Experimental MRNA Cancer Treatment Passed a Key Test

Moderna shares more than doubled Wednesday after it announced initial results from a study of an experimental cancer treatment that would be the first of its kind if approved by regulators.

· 5h

This mRNA vaccine could potentially prevent the deadliest form of skin cancer

· 20h

Potential new skin cancer vaccine

· 22h

FirstFT: Moderna’s ‘landmark’ cancer treatment leads to share price surge

The therapy, jointly developed with Merck, would be unprecedented in cancer treatment, providing a custom-made vaccine for each patient depending on their specific tumours.

· 22h

Moderna’s Road to a Cancer Vaccine

· 22h

Moderna stock soars on results of experimental therapeutic cancer vaccine

BioSpace

Merck’s Moderna-partnered vaccine success clears view of post-Keytruda future

Investors had been pessimistic about the probability of success for the personalized cancer vaccine intismeran autogene, so the Phase 3 win was a welcome surprise.

18h

Merck upgraded at Morgan Stanley after cancer trial win; RBC downgrades

Merck (MRK) stock slips as RBC Capital Markets cuts on valuation while Morgan Stanley upgrades on trial data for Moderna (MRNA)-partnered cancer shot. Read more here.

Moderna, Merck, SK Hynix, Micron, Target, Estée Lauder, and More Stocks That Explain Today’s Market

I would like to receive updates and special offers from Dow Jones and affiliates. I can unsubscribe at any time.

'An increased ability to disease-free': Moderna CEO & Merck's Dr. Li on skin cancel vaccine trial

Stephane Bancel, Moderna CEO, and Dr. Dean Li, Merck Research Laboratories president, join 'Squawk Box' to discuss details of an experimental personalized cancer vaccine that showed positive initial results in its first-ever late-stage trial,